Lead Optimization Services of Radiopharmaceuticals
At Rdcthera, we specialize in providing comprehensive CRO services focused on the lead optimization of radiopharmaceuticals. Our expert team leverages cutting-edge technologies and methodologies to optimize the pharmacological properties, efficacy, and safety profiles of radiopharmaceutical candidates.
Lead Optimization of Radiopharmaceuticals
Radiopharmaceuticals represent a unique and rapidly advancing sector within the pharmaceutical industry, offering targeted diagnostic and therapeutic options. The lead optimization process is crucial for enhancing the specificity, stability, and bioavailability of these compounds.
Fig. 1. Relevant considerations for optimization of imaging performance with antibodies and fragments. (Carter LM, et al., 2018)
Our Lead Optimization Services
Rdcthera is a leading CRO for preclinical studies of radiopharmaceuticals, we offer a one-stop services for lead optimization of radiopharmaceuticals.
Vector Optimization Services
We offer vector optimization service, including small molecules, biologics, and nanoparticles, to enhance targeting capabilities and pharmacokinetics.
Utilizing specific buffer systems, controlled heating, and precise pH ranges to maintain vector integrity and functionality.
Tailoring vectors to meet unique project requirements and therapeutic targets.
Chelate & Radiolabeling Optimization Services
Services provided include optimization of chelation and radiolabelling, which are very important for the stability and efficiency of radiopharmaceuticals.
Long experience in chelates like DOTA, DTPA, TETA NOTA, HBED, NETA. Selection of chelating agents on the basis of optimal radionuclide binding.
Experience in various radioisotopes, such 99mTc, 68Ga, or 177Lu. We are able to find the most suitable isotope for your radiopharmaceuticals according to the needs of your project.
For maximum labelling efficiency and stability, we are able to fully test and optimize buffer systems, heating protocols and pH values.
Our bioconjugation services focus on improving the binding affinity and specificity of radiopharmaceuticals.
Utilizing both random and site-specific conjugation technologies to enhance targeting precision.
Establishing optimal conjugation conditions to maximize yield and functionality.
Implementing pretargeting, dual labeling, and multimodality approaches for complex therapeutic and diagnostic applications.
Custom Services
Recognizing each project's uniqueness, we extend services tailored to the clients' specific needs. From novel vector development to optimization of particular chelation protocols, or even bespoke bioconjugation strategies, we have earned the wherewithal for high-quality deliverables.
Our Capabilities
Advanced synthesis techniques for creating high-purity radiopharmaceutical compounds.
Rdcthera has worked with a variety of projects involving common SPECT/PET isotopes.
|
SPECT Isotopes |
| 99mTc |
123I |
111In |
201TI |
| 177Lu |
131I |
|
PET Isotopes |
| 13N |
11C |
68Ga |
18F |
| 64Cu |
89Zr |
124I |
52Mn |
Other Available Isotopes |
| 213Bi |
90Y |
225Ac |
32P |
| 3H |
14C |
|
- In Vivo and In Vitro Testing
Comprehensive testing capabilities to evaluate the efficacy and safety of optimized leads.
Ensuring all processes adhere to relevant regulatory standards, facilitating smooth transitions to clinical phases.
Our Technology Platform
Our technology platform integrates the latest innovations in development radiopharmaceuticals.
- High-Throughput Screening
Comprehensive effective and fast compound library screening to deliver hit leads for further optimization
Cutting edge analytical techniques to produce and monitor the quality of radiopharmaceuticals
Cutting-edge imaging modalities and Dosimetry analysis to support therapeutic and diagnostic radiopharmaceutical development End.
Ready to optimize your radiopharmaceutical leads? Contact us today to discuss project needs and discover the power of our expert services to achieve your goals. Rdcthera is dedicated to the advancement of the field of radiopharmaceuticals through expert lead optimization services so that your innovative compounds reach their full potential.
Reference
- Carter LM, Poty S, Sharma SK, Lewis JS. (2018). Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection. J Labelled Comp Radiopharm. 61(9):611-635.
For research use only. Not intended for any clinical use.
Related Service
